News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter
email:    
   

Acorda Therapeutics (ACOR) Announces Pricing of $300 Million Of 1.75% Convertible Senior Notes Due 2021


6/18/2014 7:02:54 AM

free biotech news Get the latest biotech news where you want it. Sign up for the free GenePool newsletter today!

ARDSLEY, N.Y.--(BUSINESS WIRE)--Acorda Therapeutics, Inc. (Nasdaq:ACOR) today announced the pricing of a public offering of $300 million principal amount of convertible senior notes due 2021 (the "Notes"). The Notes will bear interest at an annual rate of 1.75% and will mature on June 15, 2021, unless earlier converted, purchased or redeemed. Acorda granted the underwriter an option to purchase up to an additional $45 million principal amount of Notes to cover over-allotments, if any.

Hey, check out all the research scientist jobs. Post your resume today!

Read at BioSpace.com

comments powered by Disqus
   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES